Physician profile
Abigail Hook
NPI 1881256196
$7,384.09
in general payments reported to CMS, 2019-2025
24 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $892 · 2023: $1,675 · 2024: $2,269 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,217 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,216.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.78 | 2021-2025 | |
| Janssen Biotech, INC. | $1,185.69 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $568.57 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $565.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $560.63 | 2023-2025 | |
| Amgen INC. | $458.47 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $399.66 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $350.81 | 2022-2025 | Dupixent |
| Incyte Corporation | $278.94 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $252.14 | 2023-2024 | Vtama |
| Leo Pharma INC. | $243.70 | 2021-2025 | Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $214.96 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $213.99 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Biofrontera INC. | $158.76 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $140.77 | 2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.26 | 2023-2024 | Spevigo |
| Genentech USA, INC. | $108.39 | 2024-2025 | Xolair |
| Organon LLC | $73.58 | 2025 | Vtama |
| Pfizer INC. | $73.31 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $49.41 | 2023-2025 | |
| Galderma Laboratories, L.P. | $42.52 | 2025 | Nemluvio |
| Kyowa Kirin, INC. | $42.14 | 2024 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.03 | 2024 | Arazlo |
| Bioventus LLC | $20.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Hook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.